{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T12:25:19Z","timestamp":1786969519493,"version":"build-2736575974"},"reference-count":25,"publisher":"Oxford University Press (OUP)","issue":"9","license":[{"start":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T00:00:00Z","timestamp":1785801600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,8,4]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>To evaluate the tolerability and safety of extended-dosing liposomal amphotericin B (LAmB) as primary antifungal prophylaxis against invasive fungal disease (IFD) in children receiving chemotherapy for newly diagnosed acute myeloid leukaemia (AML); breakthrough proven or probable IFD was assessed as an exploratory secondary endpoint.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This retrospective, multinational, multicentre observational study included children treated for newly diagnosed AML between January 2019 and December 2023. LAmB was administered according to local protocols at 1\u2005mg\/kg three times weekly, 2.5\u2005mg\/kg twice weekly or 5\u2005mg\/kg once weekly. Clinical and laboratory adverse events (AEs) were assessed to evaluate tolerability and safety. Breakthrough proven or probable IFD, defined according to EORTC\/MSG criteria, was recorded as an exploratory secondary outcome.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Eighty-six courses of extended-dosing LAmB were analysed. The median age at first LAmB administration was 91\u2005months (IQR 26\u2013156). The median treatment duration was 13\u2005weeks (IQR 3\u201321) at a median dose of 2.7\u2005mg\/kg per infusion, with a median estimated cumulative dose of 77.6\u2005mg\/kg (IQR 21.3\u2013110.1). Clinical AEs occurred in 21% of courses, predominantly skin rash and lumbosacral pain. Laboratory AEs were mainly hypokalaemia (48%) and hepatotoxicity (19%), both dose related. Treatment discontinuation due to toxicity occurred in 15% of courses. Breakthrough proven or probable IFD occurred in 3% of cases.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Extended-dosing LAmB represents a reasonably well-tolerated mould-active option for primary antifungal prophylaxis in children with newly diagnosed AML, particularly when triazoles are contraindicated or daily intravenous echinocandin administration is impractical; the low observed rate of breakthrough IFD should be interpreted cautiously given the absence of a comparator group.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/jac\/dkag289","type":"journal-article","created":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T11:49:54Z","timestamp":1786016994000},"source":"Crossref","is-referenced-by-count":0,"title":["Liposomal amphotericin B retrospective multicentre study on mycosis prophylaxis (L-AmB_RUSCO): tolerability and safety of extended-dosing primary antifungal prophylaxis in children with newly diagnosed acute myeloid leukaemia"],"prefix":"10.1093","volume":"81","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4992-598X","authenticated-orcid":false,"given":"Erica","family":"Ricci","sequence":"first","affiliation":[{"name":"Infectious Disease Unit, Department of Paediatrics, IRCCS Istituto Giannina Gaslini , Genoa ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0593-4112","authenticated-orcid":false,"given":"Alessio","family":"Mesini","sequence":"additional","affiliation":[{"name":"Infectious Disease Unit, Department of Paediatrics, IRCCS Istituto Giannina Gaslini , Genoa ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2989-7301","authenticated-orcid":false,"given":"Marcello","family":"Mariani","sequence":"additional","affiliation":[{"name":"Infectious Disease Unit, Department of Paediatrics, IRCCS Istituto Giannina Gaslini , Genoa ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppina","family":"Aloj","sequence":"additional","affiliation":[{"name":"Department of Oncology, Hematology and Cellular Therapies\u2014A.O.R.N. Santobono-Pausilipon , Naples ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bianca","family":"Macri","sequence":"additional","affiliation":[{"name":"Department of Translational Medical Sciences, Pediatric Section, University of Naples Federico II , Naples ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2035-8291","authenticated-orcid":false,"given":"Natalia Ana","family":"Mendoza-Palomar","sequence":"additional","affiliation":[{"name":"Paediatric Infectious Diseases and Immunodeficiencies Unit, Children's Hospital, Vall D'Hebron Barcelona Hospital Campus , Barcelona ,","place":["Spain"]},{"name":"Infection and Immunity in Children Research Group\u2014Vall D\u2019Hebron Research Institute , Barcelona ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Blanca","family":"Espinosa-L\u00f3pez","sequence":"additional","affiliation":[{"name":"Pediatric Oncology and Hematology Department- Children's Hospital, Vall D'Hebron Barcelona Hospital Campus , Barcelona ,","place":["Spain"]},{"name":"Childhood Cancer and Blood Disorders Research Group, Vall D\u2019Hebron Institut de Recerca , Barcelona, Catalonia ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kim","family":"Buntrock","sequence":"additional","affiliation":[{"name":"Department of Pediatrics Division of Hematology, Oncology and Hemostaseology; Goethe University Frankfurt , Frankfurt am Main ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathrin","family":"Gordon","sequence":"additional","affiliation":[{"name":"Infectious Disease Research Program, Center for Bone Marrow Transplantation and Department of Pediatric Hematology\/Oncology, University Children\u2019s Hospital M\u00fcnster , M\u00fcnster ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"De Leonardis","sequence":"additional","affiliation":[{"name":"Division of Paediatric Haematology and Oncology\u2014Azienda Ospedaliero Universitaria Consorziale Policlinico , Bari ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberta","family":"Koronica","sequence":"additional","affiliation":[{"name":"Division of Paediatric Haematology and Oncology\u2014Azienda Ospedaliero Universitaria Consorziale Policlinico , Bari ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Ferreras-Antolin","sequence":"additional","affiliation":[{"name":"Centre for Neonatal and Paediatric Infection, City St. George's, University of London , London ,","place":["UK"]},{"name":"Paediatric Infectious Diseases Department, Great Ormond Street Hospital, NHS Foundation Trust , London ,","place":["UK"]},{"name":"Medical Research Council Centre for Medical Mycology, Department of Biosciences, Faculty of Health and Life Sciences, University of Exeter , Exeter ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hadeel","family":"Mahjoob","sequence":"additional","affiliation":[{"name":"Paediatric Infectious Diseases Unit, St.George\u2019s University Hospital , London ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6586-3358","authenticated-orcid":false,"given":"Adilia","family":"Warris","sequence":"additional","affiliation":[{"name":"Paediatric Infectious Diseases Department, Great Ormond Street Hospital, NHS Foundation Trust , London ,","place":["UK"]},{"name":"Medical Research Council Centre for Medical Mycology, Department of Biosciences, Faculty of Health and Life Sciences, University of Exeter , Exeter ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Lehrnbecher","sequence":"additional","affiliation":[{"name":"Department of Pediatrics Division of Hematology, Oncology and Hemostaseology; Goethe University Frankfurt , Frankfurt am Main ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1188-393X","authenticated-orcid":false,"given":"Andreas H","family":"Groll","sequence":"additional","affiliation":[{"name":"Infectious Disease Research Program, Center for Bone Marrow Transplantation and Department of Pediatric Hematology\/Oncology, University Children\u2019s Hospital M\u00fcnster , M\u00fcnster ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5336-8429","authenticated-orcid":false,"given":"Elio","family":"Castagnola","sequence":"additional","affiliation":[{"name":"Infectious Disease Unit, Department of Paediatrics, IRCCS Istituto Giannina Gaslini , Genoa ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,8,17]]},"reference":[{"key":"2026081707313790900_dkag289-B1","doi-asserted-by":"publisher","first-page":"1367","DOI":"10.1093\/cid\/ciz1008","article-title":"Revision and update of the consensus definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer and the mycoses study group education and research consortium","volume":"71","author":"Donnelly","year":"2020","journal-title":"Clin Infect Dis"},{"key":"2026081707313790900_dkag289-B2","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1111\/ejh.12910","article-title":"Retrospective study on the incidence and outcome of proven and probable invasive fungal infections in high-risk pediatric onco-hematological patients","volume":"99","author":"Cesaro","year":"2017","journal-title":"Eur J Haematol"},{"key":"2026081707313790900_dkag289-B3","doi-asserted-by":"publisher","DOI":"10.3389\/fmicb.2019.00681","article-title":"Incidence and outcome of invasive fungal diseases in children with hematological malignancies and\/or allogeneic hematopoietic stem cell transplantation: results of a prospective multicenter study","volume":"10","author":"Lehrnbecher","year":"2019","journal-title":"Front Microbiol"},{"key":"2026081707313790900_dkag289-B4","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.29275","article-title":"Invasive fungal disease in children with acute myeloid leukaemia: an Australian multicentre 10-year review","volume":"68","author":"Yeoh","year":"2021","journal-title":"Pediatr Blood Cancer"},{"key":"2026081707313790900_dkag289-B5","doi-asserted-by":"publisher","first-page":"990","DOI":"10.1111\/myc.12990","article-title":"Epidemiology and outcome of invasive fungal disease in children after hematopoietic cell transplantation or treated for malignancy: impact of national programme of antifungal prophylaxis","volume":"62","author":"Czy\u017cewski","year":"2019","journal-title":"Mycoses"},{"issue":"Suppl 7","key":"2026081707313790900_dkag289-B6","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1111\/imj.15588","article-title":"Consensus guidelines for antifungal prophylaxis in haematological malignancy and haemopoietic stem cell transplantation, 2021","volume":"51","author":"Teh","year":"2021","journal-title":"Intern Med J"},{"key":"2026081707313790900_dkag289-B7","doi-asserted-by":"publisher","first-page":"e254","DOI":"10.1016\/s1470-2045(20)30723-3","article-title":"8th European Conference on Infections in Leukaemia: 2020 guidelines for the diagnosis, prevention, and treatment of invasive fungal diseases in paediatric patients with cancer or post-haematopoietic cell transplantation","volume":"22","author":"Groll","year":"2021","journal-title":"Lancet Oncol"},{"key":"2026081707313790900_dkag289-B8","doi-asserted-by":"publisher","first-page":"3205","DOI":"10.1200\/jco.20.00158","article-title":"Clinical practice guideline for systemic antifungal prophylaxis in pediatric patients with Cancer and hematopoietic stem-cell transplantation recipients","volume":"38","author":"Lehrnbecher","year":"2020","journal-title":"J Clin Oncol"},{"key":"2026081707313790900_dkag289-B9","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1080\/17474086.2024.2390639","article-title":"Challenges and considerations for antifungal prophylaxis in children with acute myeloid leukemia","volume":"17","author":"Yeoh","year":"2024","journal-title":"Expert Rev Hematol"},{"key":"2026081707313790900_dkag289-B10","doi-asserted-by":"publisher","first-page":"985","DOI":"10.1080\/14787210.2025.2574707","article-title":"Fungal infections in pediatric patients: challenges and considerations in treatment","volume":"23","author":"Castagnola","year":"2025","journal-title":"Expert Rev Anti Infect Ther"},{"key":"2026081707313790900_dkag289-B11","doi-asserted-by":"publisher","first-page":"1673","DOI":"10.1001\/jama.2019.15702","article-title":"Effect of caspofungin vs fluconazole prophylaxis on invasive fungal disease among children and young adults with acute myeloid leukemia: a randomized clinical trial","volume":"322","author":"Fisher","year":"2019","journal-title":"JAMA"},{"key":"2026081707313790900_dkag289-B12","doi-asserted-by":"publisher","DOI":"10.1128\/cmr.00010-19","article-title":"Extended dosing regimens for fungal prophylaxis","volume":"32","author":"Lehrnbecher","year":"2019","journal-title":"Clin Microbiol Rev"},{"key":"2026081707313790900_dkag289-B13","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/j.idc.2015.10.012","article-title":"Antifungal agents: Spectrum of activity, pharmacology, and clinical indications","volume":"30","author":"Nett","year":"2016","journal-title":"Infect Dis Clin North Am"},{"key":"2026081707313790900_dkag289-B14","doi-asserted-by":"publisher","first-page":"802","DOI":"10.1093\/jac\/dkae479","article-title":"Efficacy and safety of posaconazole and liposomal amphotericin B use for prophylaxis of invasive fungal infections in a paediatric and young adult haemato-oncological population","volume":"80","author":"Chiusaroli","year":"2025","journal-title":"J Antimicrob Chemother"},{"key":"2026081707313790900_dkag289-B15","doi-asserted-by":"publisher","first-page":"1792","DOI":"10.1093\/jac\/dkaf171","article-title":"Liposomal amphotericin B prophylaxis in paediatrics: a systematic review","volume":"80","author":"Thorley","year":"2025","journal-title":"J Antimicrob Chemother"},{"key":"2026081707313790900_dkag289-B16","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1086\/590566","article-title":"Defining responses to therapy and study outcomes in clinical trials of invasive fungal diseases: mycoses study group and European organization for research and treatment of Cancer consensus criteria","volume":"47","author":"Segal","year":"2008","journal-title":"Clin Infect Dis"},{"key":"2026081707313790900_dkag289-B17","author":"National Cancer Institute"},{"key":"2026081707313790900_dkag289-B18","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbi.2019.103208","article-title":"The REDCap consortium: building an international community of software platform partners","volume":"95","author":"Harris","year":"2019","journal-title":"J Biomed Inform"},{"key":"2026081707313790900_dkag289-B19","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1016\/j.jbi.2008.08.010","article-title":"Research electronic data capture (REDCap)\u2014A metadata-driven methodology and workflow process for providing translational research informatics support","volume":"42","author":"Harris","year":"2009","journal-title":"J Biomed Inform"},{"key":"2026081707313790900_dkag289-B20","doi-asserted-by":"publisher","DOI":"10.1016\/j.lanwpc.2024.101201","article-title":"Invasive fungal disease and antifungal prophylaxis in children with acute leukaemia: a multicentre retrospective Australian cohort study","volume":"52","author":"Yeoh","year":"2024","journal-title":"Lancet Reg Health West Pac"},{"key":"2026081707313790900_dkag289-B21","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V116.21.1071.1071","article-title":"Severe toxicities during pediatric acute myeloid leukemia chemotherapy: a report from the children's oncology group","volume":"116","author":"Sung","year":"2010","journal-title":"Blood"},{"key":"2026081707313790900_dkag289-B22","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1097\/mph.0000000000001468","article-title":"Frequency and determinants of invasive fungal infections in children with solid and hematologic malignancies in a nonallogeneic stem cell transplantation setting: a narrative review","volume":"41","author":"Ruijters","year":"2019","journal-title":"J Pediatr Hematol Oncol"},{"key":"2026081707313790900_dkag289-B23","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1016\/j.jmii.2016.08.011","article-title":"Clinical characteristics and outcome of invasive fungal infections in pediatric acute myeloid leukemia patients in a medical center in Taiwan","volume":"51","author":"Lin","year":"2018","journal-title":"J Microbiol Immunol Infect"},{"key":"2026081707313790900_dkag289-B24","doi-asserted-by":"publisher","first-page":"1439","DOI":"10.1016\/j.ejca.2005.03.007","article-title":"Bloodstream infections and invasive mycoses in children undergoing acute leukaemia treatment: a 13-year experience at a single Italian institution","volume":"41","author":"Castagnola","year":"2005","journal-title":"Eur J Cancer"},{"key":"2026081707313790900_dkag289-B25","doi-asserted-by":"publisher","first-page":"1103","DOI":"10.1002\/pbc.22750","article-title":"Incidence of bacteremias and invasive mycoses in children with acute non-lymphoblastic leukemia: results from a multi-center Italian study","volume":"55","author":"Castagnola","year":"2010","journal-title":"Pediatr Blood Cancer"}],"container-title":["Journal of Antimicrobial Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jac\/article-pdf\/81\/9\/dkag289\/70664150\/dkag289.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jac\/article-pdf\/81\/9\/dkag289\/70664150\/dkag289.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T11:31:45Z","timestamp":1786966305000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jac\/article\/doi\/10.1093\/jac\/dkag289\/8762444"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,4]]},"references-count":25,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,8,4]]}},"URL":"https:\/\/doi.org\/10.1093\/jac\/dkag289","relation":{},"ISSN":["0305-7453","1460-2091"],"issn-type":[{"value":"0305-7453","type":"print"},{"value":"1460-2091","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,9]]},"published":{"date-parts":[[2026,8,4]]},"article-number":"dkag289"}}